report
chloroquin
effect
inhibitor
replic
sever
acut
respiratori
syndrom
coronaviru
sarscov
vitro
chloroquin
clinic
approv
drug
effect
malaria
test
chloroquin
phosphat
antivir
potenti
sarscovinduc
cytopath
vero
cell
cultur
result
indic
ic
chloroquin
antivir
activ
lm
significantli
lower
cytostat
activ
cc
lm
yield
select
index
ic
chloroquin
inhibit
sarscov
vitro
approxim
plasma
concentr
chloroquin
reach
treatment
acut
malaria
addit
chloroquin
infect
cultur
could
delay
h
postinfect
without
import
drop
antivir
activ
chloroquin
old
antimalari
drug
may
consid
immedi
use
prevent
treatment
sarscov
infect
sever
acut
respiratori
syndrom
sar
recent
emerg
new
highli
contagi
human
diseas
major
impact
world
global
sar
epidem
start
guangdong
provinc
southern
china
sever
case
atyp
pneumonia
unknown
etiolog
report
end
novemb
novel
member
coronavirida
famili
identifi
caus
agent
sar
three
human
coronavirus
hcov
recent
character
import
caus
upper
respiratori
tract
ill
late
fall
winter
respons
approxim
onethird
common
cold
epidem
treatment
sar
empir
due
limit
understand
new
diseas
proteas
inhibitor
lopinavirritonavir
combin
ribavirin
may
benefit
antivir
therapi
given
earli
phase
ill
role
interferon
system
steroid
prevent
immunemedi
lung
injuri
requir
investig
sinc
epidem
lot
effort
put
antivir
research
find
compound
effect
sarscov
glycyrrhizin
activ
compon
liquoric
root
niclosamid
antihelminth
drug
nelfinavir
human
immunodefici
defici
viru
hiv
proteas
inhibitor
snap
nitric
oxid
donor
report
antivir
effect
sarscov
savarino
et
al
hypothes
chloroquin
might
use
clinic
manag
sar
chloroquin
known
antimalari
agent
elicit
also
antivir
effect
sever
virus
includ
hiv
type
hepat
b
viru
herp
simplex
viru
type
antivir
effect
chloroquin
hiv
type
replic
current
test
clinic
see
front
matter
elsevi
inc
right
reserv
trial
besid
direct
antivir
effect
chloroquin
endow
immunomodulatori
activ
suppress
product
releas
tumour
necrosi
factor
interleukin
mediat
inflammatori
complic
sever
viral
diseas
studi
evalu
chloroquin
potenti
protect
sarscov
infect
vitro
compound
test
chloroquin
phosphat
diethylamino
amino
quinolin
phosphat
alpha
pharma
belgium
interferon
avonex
biogen
use
posit
control
realtim
quantit
rtpcr
realtim
quantit
rtpcr
taqman
design
put
region
replicas
domain
sarsassoci
coronaviru
sarscov
genom
forward
primer
sarsfp
mgb
probe
sarstp
fam
nfqmgb
revers
primer
sarsrp
ttgcatgacagc
rtpcr
carri
use
extract
rna
standard
crna
taqman
onestep
rtpcr
master
mix
contain
rox
passiv
refer
appli
biosystem
foster
citi
ca
usa
nm
forward
revers
primer
nm
mgb
probe
amplif
detect
perform
abi
prism
sequenc
detect
system
appli
biosystem
foster
citi
ca
usa
follow
condit
initi
revers
transcript
min
follow
pcr
activ
min
cycl
amplif
min
amplif
abi
prism
sequenc
detector
monitor
realtim
pcr
amplif
quantit
analys
fluoresc
emiss
report
dye
fam
signal
measur
intern
refer
dye
rox
signal
normal
nonpcrrel
fluoresc
fluctuat
occur
well
well
threshold
cycl
repres
refract
cycl
number
posit
amplif
measur
set
time
standard
deviat
mean
baselin
emiss
calcul
pcr
cycl
construct
crna
standard
taqman
sarscov
forward
primer
modifi
sequenc
end
taatacgactcactatagggaggcacccgc
pcr
product
amplifi
modifi
primer
pair
quantifi
spectrophotometr
nm
two
hundr
nanogram
pcr
product
use
vitro
transcript
megashortscript
kit
ambion
austin
tx
usa
perform
overnight
period
reaction
mix
contain
reaction
buffer
ntp
enzym
mix
cdna
remov
digest
u
rnasefre
dnase
min
crna
precipit
ad
naoac
etoh
subsequ
incub
min
min
centrifug
rpm
supernat
remov
etoh
ad
anoth
min
centrifug
rpm
supernat
remov
pellet
dissolv
rnase
free
h
sigmaaldrich
nv
bornem
belgium
store
quantif
crna
perform
spectrophotometr
nm
measur
crna
concentr
perform
duplic
convert
molecul
number
antivir
assay
antivir
activ
cytotox
measur
base
viabil
cell
infect
infect
ccid
cell
cultur
infect
dose
sarscov
presenc
variou
concentr
test
compound
three
day
infect
number
viabl
cell
quantifi
tetrazoliumbas
colorimetr
method
reduct
mt
dye
celltit
aqueou
one
solut
kit
promega
netherland
cellular
dehydrogenas
insolubl
colour
formazan
measur
spectrophotomet
multiskan
ex
thermo
labsystem
belgium
nm
select
index
determin
ratio
concentr
compound
reduc
cell
viabil
cc
cytotox
concentr
concentr
compound
need
inhibit
viral
cytopath
effect
control
valu
ic
inhibitori
concentr
interferon
b
use
posit
control
timeofaddit
assay
subconflu
monolay
vero
cell
plate
infect
ccid
sarscov
min
adsorpt
cell
monolay
wash
five
time
mem
chloroquin
ad
concentr
ic
lm
triplic
time
infect
differ
time
point
thereaft
eight
hour
infect
time
first
viral
cycl
complet
cell
supernat
collect
viral
rna
extract
antivir
activ
determin
use
quantit
rtpcr
describ
viru
yield
assay
incub
virusinfect
vero
cell
differ
concentr
test
compound
appropri
condit
supernat
contain
free
virus
subject
quantit
rtpcr
viru
titer
determin
day
day
postinfect
studi
report
vitro
antivir
activ
chloroquin
sarscov
frankfurt
strain
infect
cytotox
vero
cell
measur
parallel
antivir
activ
experi
done
quadrupl
repeat
three
time
repres
result
shown
fig
viru
yield
assay
viral
rna
quantifi
one
three
day
postinfect
signific
replic
observ
one
day
cell
treat
lm
chloroquin
inhibit
viru
replic
three
day
postinfect
lm
chloroquin
need
fig
obtain
initi
insight
stage
viral
replic
cycl
chloroquin
may
exert
antivir
activ
timeofdrugaddit
assay
elabor
vero
cell
infect
ccid
sarscov
one
viru
replic
cycl
take
h
therefor
quantit
effect
viral
replic
h
postinfect
ie
time
point
progeni
viru
supernat
sole
deriv
first
replic
cycl
compound
prove
equal
activ
ad
adsorpt
h
infect
indic
viru
like
interfer
earli
step
viral
replic
ie
attach
penetr
later
time
point
gradual
loss
antivir
activ
chloroquin
note
fig
ic
chloroquin
inhibit
sarscov
replic
vero
cell
lm
plasma
concentr
chloroquin
reach
human
plasma
follow
treatment
chloroquin
acut
malaria
dose
mgkg
three
day
dose
chloroquin
use
treatment
rheumatoid
arthriti
mgkg
gener
plasma
chloroquin
concentr
lm
concentr
rang
ic
inhibit
sarscov
result
show
chloroquin
inhibit
replic
sarscov
vero
cell
sinc
immunopatholog
factor
may
play
signific
role
sarscov
interest
studi
whether
chloroquin
also
effect
term
modul
inflammatori
respons
sarscov
infect
chloroquin
given
prophylact
dose
mgweek
peopl
travel
malaria
endem
area
sar
reemerg
chloroquin
great
import
prophylact
medic
peopl
live
travel
affect
area
chloroquin
ubiquit
avail
low
cost
easi
administ
may
consid
immedi
use
prevent
treatment
sarscov
infect
research
univers
leuven
belgium
help
comment
discuss
work
support
fellowship
flemish
fond
voor
wetenschappelijk
onderzoek
fwo
leen
vijgen
fwogrant
